Table 4.
The clinical trials of oncolytic viruses in patients with pancreatic cancer.
| Oncolytic Virus | Clinical Trial Phase | Administration Route | Combination | Status | Trial No | Reference |
|---|---|---|---|---|---|---|
| T-VEC (Talimogene laherparepvec) | I | IT | ---- | Completed | NCT00402025 | [93] |
| I | IT | -- | Recruiting | NCT03086642 | ||
|
HF10
(canerpaturev, C-REV) |
IIT | IT | ---- | Completed | PMID29801474 | [91,92] |
| I | IT | Nab-Paclitaxel + Gemcitabine/S-1 | Ongoing | NCT03252808 | ||
| OrienX010 | I | IT | ---- | Ongoing | NCT01935453 | |
| ONYX-015 | I | IT | ---- | Completed | PMID11313805 | [89] |
| II | IT | Gemcitabine | Completed | PMID12576418 | [90] | |
| VCN-01 | I | IT &IV | Nab-Paclitaxel/Gemcitabine | Recruiting | NCT02045589 | |
| LOAd703 | I | IT | Gemcitabine | Recruiting | NCT02705196 | |
| Parvovirus H-1 (ParvOryx) | I | IT & IV | ---- | Recruiting | NCT02653313 | |
|
Pelareorep (Reolysin®) |
II | IV | Carboplatin/paclitaxel | Completed | NCT01280058 | [94] |
| II | IV | Gemcitabine | Completed | NCT00998322 | [95] | |
| I | IV | Pembrolizumab | Ongoing | NCT02620423 |